Here's what workplaces young professionals are the most happy. Photo via Getty Images

Ten businesses in the Greater Houston area are clocking in among the country's best employers for millennials, according to a new report.

The Best Workplaces for Millennials list is published annually by Fortune magazine and compiled by Great Place to Work, a company that focuses on improving workplace culture.

Looking at the 10 Houston-area employers, mega developer David Weekley homes takes the top spot. The company appears at No. 12 on the list of large employers.

"It's an honor to once again be recognized as a top company for working millennials," said Robert Hefner, David Weekly vice president of human resources, in a statement. "We are very proud to offer a rewarding workplace culture as well as competitive benefits and amazing perks to draw this group of young talent to our award-winning team."

In that survey, 97 percent of staffers called David Weekley Homes a great place to work. The home builder previously ranked at number 26 on the 2020 list.

Joining David Weekly on the list are these large, mid-size, and small Houston-area companies:

Large employers:

  • Camden Property Trust, No. 32
  • Hilcorp, No. 37
  • Cornerstone Home Lending, No. 38
  • Transwestern, No. 65
  • Hewlett Packard Enterprise, No. 95

Small and mid-sized employers:

  • Continued, No. 33
  • Venterra Realty, No. 49
  • Republic State Mortgage, No. 90
  • E.A.G. Services, No. 91

Here's how employers in Texas' other major metro areas fared.

Dallas

  • Plano-based Granite: No. 6
  • Addison-based Credera, No. 36
  • Dallas-based Pariveda Solutions, No. 76
  • Dallas-based Embark, No. 97
  • Dallas-based PrimeLending lands at No. 29
  • Dallas-based Ryan LLC at No. 35.

Austin

Large employers:

  • Round Rock-based Dell Technologies, No. 75

Small and mid-sized employers:

  • Austin-based OJO Labs, No. 51
  • Austin-based SailPoint, No. 60
  • Austin-based Sedera Health, No. 69
  • Austin-based The Zebra, No. 86

San Antonio

Large employers:

  • San Antonio-based NuStar Energy, No. 91
  • San Antonio-based USAA, No. 98

"The Best Workplaces for Millennials treat their employees like people, not just employees," says Michael Bush, CEO of Great Place to Work. "These companies foster caring and respect for one another, at every level of the organization. The result is millennial employees who say they look forward to coming to work and — as our research says — are 50 times more likely to stay a long time."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”